Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs

Journal of Infectious Diseases

Volumn 177, Issue 5, 1998, Pages 1143-1154

  Spector, Frances C ^a   Kern, Earl R ^c   Palmer, Joyce ^c   Kaiwar, Ravi ^c   Cha, Tai An ^c   Brown, Peter ^b   Spaete, Richard R ^c  

^a AMGEN INC   (United States)

^b Avigen Inc   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; HERPES VACCINE; HERPES VACCINE RAV9395; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; GENE DELETION; GUINEA PIG; HERPES SIMPLEX VIRUS 2; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; STRAIN DIFFERENCE; VACCINATION; VIRUS REACTIVATION; VIRUS RECOMBINATION; VIRUS VIRULENCE;

EID: 0031948661     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515278     Document Type: Article

References (18)

1. Whitley RJ. Herpes simplex viruses. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. Chapter 73. New York: Lippincott-Raven Press, 1996:2297-342.
2. Inglis SC. Challenges and progress in developing herpesvirus vaccines. Tibtech 1995;13:135-42.
3. Nahmias AJ, Keyserling HL, Lee FK. Herpes simplex viruses 1 and 2. In: Evans AS, ed. Viral infections of humans. Epidemiology and control. 3rd ed. New York: Plenum Press, 1989:393-417.
4. Corey L. The natural history of genital herpes simplex virus. Perspectives on an increasing problem. In: Roizman B, Lopez C, eds. The herpesviruses. Immunobiology and prophylaxis of human herpesvirus infections. Vol 4. New York: Plenum Press, 1985:1-35.
5. Corey L, Spear PG. Infections with herpes simplex viruses. N Engl J Med 1986;314:686-91.
6. Burke RL. Contemporary approaches to vaccination against herpes simplex virus. Curr Top Microbiol Immunol 1992;79:137-58.
7. Burke RL. Current status of HSV vaccine development. In: Roizman B, Whitley RJ, Lopez C, eds. The human herpesviruses. New York: Raven Press, 1993:367-79.
8. Peter G. Childhood immunizations. N Engl J Med 1992; Dec 17: 1794-800.
9. Plotkin SA. Vaccines for varicella-zoster virus and cytomegalovirus: recent progress. Science 1994;265:1383-5.
10. Roizman B, Sears AE. Herpes simplex viruses and their replication. In: Roizman B, Whitley RJ, Lopez C. eds. The human herpesviruses. New York: Raven Press, 1993:11-68.
11. 134.5, a gene nonessential to growth in culture. Science 1990;250:1262-6.
12. Meignier B, Longnecker R, Mavromara-Nazos P, Sears AE, Roizman B. Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus. J Virol 1988;162:251-4.
13. Spivak JG, Fareed MU, Valyi-Nagy T, et al. Replication, establishment of latent infection, expression of the latency-associated transcripts and expiant reactivation of herpes simplex virus type 1 gamma 34.5 mutants in a mouse eye model. J Gen Virol 1995;76:321-32.
14. Robertson LM, MacLean AR, Brown SM. Peripheral replication and latency reactivation kinetics of the nonneurovirulent herpes simplex virus 1 variant 1716. J Gen Virol 1992;73:967-70.
15. +. J Virol 1990;64:1014-20.
16. Whitley RJ, Kern ER, Chatterjee S, Chou J, Roizman B. Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma-I 34.5 deletion mutants in rodent models. J Clin Invest 1993;91:2837-43.
17. Lagunoff M, Roizman B. The regulation of synthesis and properties of the protein product of open reading frame P of the herpes simplex virus 1 genome. J Virol 1995;69:3615-23.
18. Whitley RJ, Gann JW Jr. Acyclovir: A decade later. N Engl J Med 1992; 327:782-9.